Back
Compare AU
Compare IEM vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares MSCI Emerging Markets ETF (IEM) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IEM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 300 | 74 |
Median incremental investment | $1,356.41 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,866.30 | $1,587.12 |
Average age group | > 35 | > 35 |
Key Summary
IEM | DRUG | |
|---|---|---|
Strategy | IEM.AX was created on 2003-04-07 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the equity market performance in global emerging markets. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | ISH MSCI EM USD ETF DIST (99.96 %) USD CASH (0.03 %) EUR CASH (0.01 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) |
Top 3 industries | Other (99.99 %) Communication Services (0.01 %) Information Technology (0.00 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | China (25.52 %) Taiwan (21.12 %) Korea (14.60 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.69 % | 0.57 % |
Key Summary
IEM | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | MSCI EM (Emerging Markets) | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.57 % |
Price | $84.05 | $8.51 |
Size | $1.532 billion | $176.152 million |
10Y return | 87.99 % | N/A |
Annual distribution yield (5Y) | 1.88 % | 1.92 % |
Market | ASX | ASX |
First listed date | 10/10/2007 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IEM | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 300 | 74 |
Median incremental investment | $1,356.41 | $745.07 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,866.30 | $1,587.12 |
Average age group | > 35 | > 35 |
Pros and Cons
IEM | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IEM | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |